Patents Assigned to Indi Molecular, Inc.
  • Compositions, delivery systems, and methods useful in tumor therapy
    Patent number: 11766414
    Abstract: Disclosed are compounds, compositions, systems, and methods useful for treating disease (such as cancer and tumors), or binding, detecting, and affecting compounds, compositions, cells, tissues, and organs, where the compounds, compositions, systems, and methods include or involve toxic compounds and where the toxic effect of the compounds, compositions, systems, and methods is reduced by providing a cleavage site to facilitate separation of the toxic component from other components of the compound, composition, or system. Preferably the system is a composition delivery system comprising or using a composition as disclosed herein. In some forms, the cleavage of the composition delivers a therapeutic agent and avoids organ damage by the composition.
    Type: Grant
    Filed: January 17, 2022
    Date of Patent: September 26, 2023
    Assignee: INDI MOLECULAR, INC.
    Inventors: Heather Dawn Agnew, Anders Eliasen, Bert Tsunyin Lai
  • Compositions, imaging, and therapeutic methods targeting folate receptor 1 (FOLR1)
    Patent number: 11733246
    Abstract: The present application provides stable heterobiligands made up of peptide-based FOLR1 ligands and folate (the ligand of FOLR1) and methods of use of the heterobiligands as detection, imaging, diagnostic, and therapeutic agents. The application further provides methods of manufacturing FOLR1 heterobiligands, capture agents, and imaging agents.
    Type: Grant
    Filed: January 12, 2022
    Date of Patent: August 22, 2023
    Assignee: INDI MOLECULAR, INC.
    Inventors: Heather Dawn Agnew, Anders Eliasen, Bert Tsunyin Lai
  • Botulinum neurotoxin-specific capture agents, compositions, and methods of using and making
    Patent number: 11723944
    Abstract: The present application provides stable peptide-based Botulinum neurotoxin (BoNT) serotype A capture agents and methods of use as detection and diagnosis agents and in the treatment of diseases and disorders. The application further provides methods of manufacturing BoNT serotype A capture agents using iterative on-bead in situ click chemistry.
    Type: Grant
    Filed: May 17, 2021
    Date of Patent: August 15, 2023
    Assignees: INDI MOLECULAR, INC., CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Blake Farrow, James R. Heath, Heather Dawn Agnew
  • IL-17F and IL-17A-specific capture agents, compositions, and methods of using and making
    Patent number: 11719705
    Abstract: The present application provides stable peptide-based IL-17F and IL-17A capture agents and methods of use as detection agents. The application further provides methods of manufacturing IL-17F capture agents.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: August 8, 2023
    Assignees: INDI MOLECULAR, INC., CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Heather Agnew, Bert Tsunyin Lai, Suresh Mark Pitram, Blake Farrow, James R. Heath, David Bunck, Jingxin Liang, Arundhati Nag, Samir Das
  • Theranostic capture agents, compositions, and methods of using and making
    Patent number: 11638764
    Abstract: Disclosed are compounds, compositions, and methods involving theranostic capture agent for a target where the capture agent is (a) a precursor that can be loaded with a detectable moiety, a therapeutic moiety, or both, (b) loaded with a detectable moiety, (c) loaded with a therapeutic moiety, or (d) loaded with both a detectable moiety and a therapeutic moiety. Also disclosed are stable peptide-based PSMA capture agents and methods of use as detection agents.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: May 2, 2023
    Assignee: INDI MOLECULAR, INC.
    Inventor: Heather Agnew
  • Botulinum neurotoxin-specific capture agents, compositions, and methods of using and making
    Patent number: 11007245
    Abstract: The present application provides stable peptide-based Botulinum neurotoxin (BoNT) serotype A capture agents and methods of use as detection and diagnosis agents and in the treatment of diseases and disorders. The application further provides methods of manufacturing BoNT serotype A capture agents using iterative on-bead in situ click chemistry.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: May 18, 2021
    Assignees: INDI MOLECULAR, INC., CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Blake Farrow, James R. Heath, Heather Dawn Agnew
  • IL-17F-specific capture agents, compositions, and methods of using and making
    Patent number: 10598671
    Abstract: The present application provides stable peptide-based IL-17F capture agents and methods of use as detection agents. The application further provides methods of manufacturing IL-17F capture agents.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: March 24, 2020
    Assignees: Indi Molecular, Inc., California Institute of Technology
    Inventors: James R. Heath, Heather Agnew, Blake Farrow, David Bunck, Jingxin Liang, Arundhati Nag, Samir Das, Bert Tsunyin Lai, Suresh Mark Pitram
  • Akt-specific capture agents, compositions, and methods of using and making
    Patent number: 10221214
    Abstract: The present application provides stable peptide-based Akt capture agents and the use thereof as detection, diagnosis, and treatment agents. The application further provides novel methods of developing stable peptide-based capture agents, including Akt capture agents, using iterative on-bead in situ click chemistry.
    Type: Grant
    Filed: November 23, 2015
    Date of Patent: March 5, 2019
    Assignee: INDI MOLECULAR, INC.
    Inventors: James R. Heath, Arundhati Nag, Samir Das, Kaycie M. Deyle, Steven Wesley Millward, Paul Edward Kearney
  • Botulinum neurotoxin-specific capture agents, compositions, and methods of using and making
    Patent number: 9913875
    Abstract: The present application provides stable peptide-based Botulinum neurotoxin (BoNT) serotype A capture agents and methods of use as detection and diagnosis agents and in the treatment of diseases and disorders. The application further provides methods of manufacturing BoNT serotype A capture agents using iterative on-bead in situ click chemistry.
    Type: Grant
    Filed: March 16, 2016
    Date of Patent: March 13, 2018
    Assignees: California Institute of Technology, Indi Molecular, Inc.
    Inventors: Blake Farrow, James R. Heath, Heather Dawn Agnew
  • Akt-specific capture agents, compositions, and methods of using and making
    Patent number: 9239332
    Abstract: The present application provides stable peptide-based Akt capture agents and the use thereof as detection, diagnosis, and treatment agents. The application further provides novel methods of developing stable peptide-based capture agents, including Akt capture agents, using iterative on-bead in situ click chemistry.
    Type: Grant
    Filed: July 11, 2012
    Date of Patent: January 19, 2016
    Assignee: INDI MOLECULAR, INC.
    Inventors: James R. Heath, Arundhati Nag, Samir Das, Kaycie M. Deyle, Steven Wesley Millward, Paul Edward Kearney
  • VEGF-specific capture agents, compositions, and methods of using and making
    Patent number: 9221889
    Abstract: The present application provides biligand and triligand protein-catalyzed capture (PCC) agents that specifically bind VEGF, as well as the use of these capture agents as detection, diagnosis, and treatment agents.
    Type: Grant
    Filed: January 7, 2014
    Date of Patent: December 29, 2015
    Assignee: INDI MOLECULAR, INC.
    Inventors: Suresh Mark Pitram, Heather Dawn Agnew, Tsun Yin Lai, Rosemary Dyane Rohde, Paul Edward Kearney, Scott Law, Kenneth Charles Fang
  • PSA capture agents, compositions, methods and preparation thereof
    Patent number: 8841083
    Abstract: Disclosed herein are novel synthetic prostate specific antigen (PSA)-targeted capture agents that specifically bind PSA. In certain embodiments, these PSA capture agents are biligand or triligand capture agents containing two or three target-binding moieties, respectively.
    Type: Grant
    Filed: February 3, 2012
    Date of Patent: September 23, 2014
    Assignees: California Institute of Technology, Indi Molecular, Inc.
    Inventors: James R. Heath, Heather Dawn Agnew, Suresh Mark Pitram
  • VEGF-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING
    Publication number: 20140256630
    Abstract: The present application provides biligand and triligand protein-catalyzed capture (PCC) agents that specifically bind VEGF, as well as the use of these capture agents as detection, diagnosis, and treatment agents.
    Type: Application
    Filed: January 7, 2014
    Publication date: September 11, 2014
    Applicant: Indi Molecular, Inc.
    Inventors: Suresh Mark PITRAM, Heather Dawn AGNEW, Tsun Yin LAI, Rosemary Dyane ROHDE, Paul Edward Kearney, Scott LAW, Kenneth Charles FANG
  • VEGF-specific capture agents, compositions, and methods of using and making
    Patent number: 8710180
    Abstract: The present application provides biligand and triligand protein-catalyzed capture (PCC) agents that specifically bind VEGF, as well as the use of these capture agents as detection, diagnosis, and treatment agents.
    Type: Grant
    Filed: August 31, 2012
    Date of Patent: April 29, 2014
    Assignee: Indi Molecular, Inc.
    Inventors: Suresh Mark Pitram, Heather Dawn Agnew, Tsun Yin Lai, Rosemary Dyane Rohde, Paul Edward Kearney